Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIIA Hepatocellular Carcinoma AJCC V8: early-phase trial registry
4 of 9 indexed Stage IIIA Hepatocellular Carcinoma AJCC V8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Stage IIIA Hepatocellular Carcinoma AJCC V8: 9 US clinical trials tracked, 4 recruiting.
Stage IIIA Hepatocellular Carcinoma AJCC V8 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Academic and Community Cancer Research United, running 2 of these trials.
Enrollment posture brief
Registry condition stage-iiia-hepatocellular-carcinoma-ajcc-v8
OPEN 4 | RECR 44% | LATE 0 | EARLY 8 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Stage IIIA Hepatocellular Carcinoma AJCC V8 lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIIA Hepatocellular Carcinoma AJCC V8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIIA Hepatocellular Carcinoma AJCC V8 is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIIA Hepatocellular Carcinoma AJCC V8 research.
Academic and Community Cancer Research United accounts for 2 of 9 trials (22.2%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IIIA Hepatocellular Carcinoma AJCC V8 trials plan to enrol fewer than 100 people.
Median target enrolment is 21 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.
-
Stage IIIA Hepatocellular Carcinoma AJCC V8 research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
NCT05168163
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
Mary Feng, MD
NCT04430452
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
NCT05103904
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
NCT04380545
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
M.D. Anderson Cancer Center
NCT03896646
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
National Cancer Institute (NCI)
NCT04175912
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
NCT04605731
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Academic and Community Cancer Research United
NCT05194293
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
Robin Kate Kelley
NCT03439891
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIIA Hepatocellular Carcinoma AJCC V8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIIA Hepatocellular Carcinoma AJCC V8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIIA Hepatocellular Carcinoma AJCC V8 page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Stage IIIA Hepatocellular Carcinoma AJCC V8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Academic and Community Cancer Research United sponsors the most Stage IIIA Hepatocellular Carcinoma AJCC V8 trials on record, review their full trial history before evaluating a specific study. See Academic and Community Cancer Research United's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIIA Hepatocellular Carcinoma AJCC V8 condition card totals 9 registered trials; most-linked intervention Durvalumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.